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2.1 Introduction 
After a drug has been administered and absorbed into the systemic circulation, it has to be 
distributed in the blood, to its site of action, where the pharmacodynamic process 
(mechanism of action, actions in the body) will take place.  The drug is then usually 
metabolised and excreted.   Distribution, metabolism and excretion are discussed in the 
following chapters.  Absorption, distribution, metabolism and excretion are all important 
determinants of the plasma levels of drugs.   The plasma levels of drugs are also discussed.  
 
2.2. Drug Distribution 
 2.2.1 Introduction 
Blood is aqueous, and only hydrophilic (water soluble) drugs will dissolve in it.  For 
absorption, most drugs have to be lipid soluble.  Lipophilic drugs are transported in the blood 
attached to proteins. 
 
 2.2.2 Protein binding 
Plasma proteins, such as albumin and globulin, were not designed to carry drugs, but are 
quite effective at doing so.  Acidic drugs bind to albumin, whereas basic drugs bind to 
globulin.   
 
In the plasma there is equilibrium (stable, balanced relationship) between the protein-bound 
and free drug (Figure 2.1).  Thus, if there is 100 ng of a drug and it is 90% bound, 10% will 
be free, and the amounts will be 90 ng bound, 10 ng free. 
 
Figure 2.1 Protein binding and distribution (Copyright QUT, Sheila Doggrell) 
 
The bound drug cannot leave the blood stream whereas the free drug (10%, 10 ng) can leave 
the circulation, often to have its pharmacodynamic effect.  When free drug leaves the blood 
vessel, more drug is released from the binding, to maintain the equilibrium (90% bound: 10% 
free; 81 ng bound: 9 ng free.  Thus, drug is gradually being released from plasma proteins. 
 
Drugs can compete for the same site on the plasma protein (Figure 2.2).  
 
Figure 2.2 Drugs competing for binding site (Copyright QUT University, Sheila Doggrell) 
 
Figure 2.2 shows drugs A and B competing for the same binding site on a plasma protein.  
Aspirin and warfarin are examples of drugs that have the same binding site on a plasma 
protein.  Aspirin and warfarin are often used together in cardiovascular disease.  Warfarin is 
used as an anti-coagulant, and the anti-coagulant effect is dependent on the free concentration 
of warfarin.  When aspirin displaces warfarin from their binding site, the free concentration 
of warfarin will be increased, and there may be too much anti-coagulation, which may lead to 
bleeding/haemorrhaging.  Thus, when both aspirin and warfarin are given to a person, it may 
be necessary to reduce the dose of warfarin. 
 
2.2.3 Levels of blood proteins and drug distribution 
 
A decrease in blood proteins leads to an increase in free drug concentration and effects, and 
the effects may go from therapeutic to toxic.  Blood proteins, especially albumin, are 
decreased most commonly by liver disease (e.g. cirrhosis).  When there are decreased plasma 
proteins, it may be necessary to decrease the dose of drug, to decrease the free concentration 
of a drug, to go from a toxic effect to a therapeutic effect.  Phenytoin is a commonly used 
anti-epileptic drug that needs to have its dose reduced in liver disease 
 
The lipid solubility of a drug is an important factor determining distribution.  Lipophilic 
drugs are accumulated in fat tissue, and are only slowly released from fat tissue: Figure 2.3  
  
Figure 2.3 Lipophilic drug accumulated and released from fat (Copyright QUT University, 
Sheila Doggrell) 
  
For instance, the anti-arrhythmic drug amiodarone is very lipophilic, and is accumulated to a 
great extent in lipids.  When the administration of amiodarone is stopped, amiodarone 
continues to be released out of the fat tissues for weeks.  Amiodarone can be a toxic drug.  
Unfortunately, the toxic effects of amiodarone are slow to reverse, as reversal requires the 
removal of amiodarone, and that may take weeks.   
 
Another example of a highly lipophilic drug is marijuana.  After a single use of marijuana, 
marijuana accumulates in the fat and is slowly released.  As a result of this, marijuana can be 
detected in blood 6 weeks after a single use. 
 
 2.2.4 Blood brain barrier 
In the systemic circulation, there are gaps between endothelial cells lining blood vessels and, 
as the basement membrane is freely permeable, this allows most free water and lipid soluble 
drugs to move out of the systemic circulation (Figure 2.4). 
 
Figure 2.4 Distribution across blood vessels (Copyright QUT University, Sheila Doggrell) 
 
In the cerebral circulation, there are no gaps between the endothelial cells, and this forms a 
barrier (referred to as the blood brain barrier), and this barrier is mainly to water soluble 
drugs.  Because of this barrier, water soluble drugs cannot get into the brain from the cerebral 
circulation.  Only lipophilic drugs, and drugs that are actively transported, can cross the blood 
brain barrier.  Most drugs used for central nervous system effects are lipophilic.  The sedative 
diazepam is a lipophilic drug that moves across lipid membranes into the brain.   
 
L-dopa is an example of a drug that it is actively transported into brain.  L-dopa is used in the 
treatment of Parkinson’s disease. 
 
The blood brain barrier is deficient in chemoreceptor trigger zone.  This allows some drugs to 
enter into this zone, and act to exert an emetic (vomiting) effect. 
 
For central nervous system effects, we need drugs that cross the blood brain barrier.  
Alternatively, drugs can be administered into the cerebral spinal fluid to bypass the blood 
brain barrier.  For instance, penicillin does not cross the blood brain barrier, which is fine 
when we have a peripheral infection, but not if the infection is within the central nervous 
system.  For central infections, penicillin has to be administered into the cerebral spinal fluid 
(CSF) by the intrathecal route of drug administration. 
 
For peripheral effects, drugs that do not cross the blood brain barrier are preferred.  This is 
because, any central effects of a drug administered for a peripheral effect, may be adverse 
effects.  For instance, the anti-histamine diphenhydramine was developed to treat allergy, a 
peripheral condition, but diphenhydramine crossed the blood brain to have central effects, 
notably a central sedative effect.  Thus, subjects given diphenhydramine for allergy were at 
risk of falling asleep.  The second generation anti-histamines (e.g. fexofenadine) were 
developed to have a reduced ability to cross the blood brain barrier and, consequently, do not 
exert a sedative effect.  Presently, only the second generation anti-histamines are used to treat 
allergy, and diphenhydramine is used as a mild sedative.  
 
2.2.4 Volume of distribution 
The volume of distribution of a drug or the (apparent) volume of distribution, as it is 
sometimes called, is not a real distribution, but a parameter that is useful in determining 
whether haemodialysis can be used to rid the body of a particular drug or whether a loading 
dose of a drug is necessary (loading doses are discussed in chapter 6.4). The volume of 
distribution is also a determinant of how frequently a drug will have to be given.  
 
The (apparent) volume of distribution Vd is defined as the volume of fluid required to contain 
the total amount of drug in the body, at the same concentration as in the plasma.  If a drug 
rapidly leaves the blood and is either widely distributed or concentrated in tissues, it will have 
a high volume of distribution – it can be much bigger than body size.  The volume of 
distribution is calculated when the drug is first developed.  Thus, we don’t need to be able to 
calculate the volume of distribution, but we do need to know how to interpret it.   
 
The volume of distribution is the total amount of drug in the body divided by the drug 
concentration.  For instance, if we compare Drugs A and B, each administered at 100 mg, we 
may find they have different plasma concentrations. This may be because they have different 
distributions and therefore different volumes of distribution.  If, after administration Drug A 
has a plasma level of 20 ng/ml, and Drug B has a plasma level of 2 ng/ml – it is obvious that 
Drug B is more widely distributed than Drug A. That is, more of Drug B is distributed 
outside of the plasma.  For Drug A, Vd is 100 mg/20 mg/L = 5 L, and for Drug B, Vd is 100 
mg/2 mg = 50 L. 
 
The plasma volume in a 70 kg adult = 3L (i.e. ~0.04 L/kg).  Any drug that is confined to 
plasma will have similar volume of distribution to the plasma (0.04 L/kg).  Drugs that are 
evenly distributed throughout body (go everywhere at same concentration as plasma) have a 
Vd of 0.57 L/kg.  Drugs that are accumulated in tissues have a greater volume of distribution. 
 
A low volume of distribution indicates that a drug is  largely confined to plasma, and can be 
removed by haemodialysis.  Conversely, drugs with a large Vd will be accumulated in fat or 
elsewhere, and cannot be removed by haemodialysis, which only removes drugs from blood.  
For instance, heparin is mainly confined to blood, has a Vd of 0.06 L/kg, and can be 
removed by haemodialysis.  Conversely, the antidepressant nortriptyline has a Vd of 14 
L/kg, due to tissue binding outside of the blood stream, and cannot be removed by 
haemodialysis.  Unfortunately, most lipid soluble drugs e.g. amiodarone have high volumes 
of distribution, due to accumulation in fat tissues, and cannot be removed by haemodialysis. 
 
2.3. Drug Metabolism 
 2.3.1 Introduction 
As we discussed previously (Section 2.2), absorption from the gastrointestinal tract is best for 
lipid soluble drugs.  Lipid soluble drugs are also readily reabsorbed from the kidney tubule.  
Thus, lipid soluble drugs are difficult to get rid of, as even when they get into the kidney 
tubule, they are reabsorbed rather than excreted.  Water soluble compounds are readily 
excreted from the kidney.  Thus, for excretion of a drug, it is necessary to turn a lipid soluble 
drug into a water soluble (hydrophilic) drug, which can then be excreted in the urine.  This 
change from a lipid soluble to a water soluble compound involves metabolism, which usually 
has two phases, Phase I and II metabolism.  In addition to increasing water solubility, 
metabolism usually produces metabolites that are inactive, and thus reduces the activity of the 
drug. 
 
Our enzyme systems are not designed to metabolise drugs.  However, the normal 
physiological enzyme pathways for metabolism of endogenous compounds (substances found 
in the body) are used in drug metabolism.  The body also has systems for metabolising 
xenobiotics (substances foreign to the body), as part of the body’s defence system.  These 
xenobiotic metabolising enzymes are also used in drug metabolism. 
 
The liver is the main site of metabolism.  Because of this, drug metabolism is changed in 
hepatic insufficiency.  However, the liver is not the only site of drug metabolism.  In addition 
to the liver, metabolising enzymes are present in high concentrations in the intestine, nasal 
mucosa and lung, and these tissues are all capable of metabolising certain drugs.  Most of the 
discussion of metabolism in this chapter is of liver metabolism. 
 
 2.3.2 Phase I 
The first phase of metabolism is Phase I.  Phase I reactions involve common chemical 
reactions such as oxidation (interaction with an oxygen), reduction (interaction with a 
hydrogen), and hydrolysis (interacting with water).   
 
The liver has a huge number of metabolising enzymes.  The best characterised metabolic 
pathways are those catalysed by cytochromes, which are haem proteins.  The Cytochrome 
P450 system (CYP) is a superfamily of distinct enzymes, known as CYP1, 2 and 3, with 
more than 50 haem-containing enzymes identified to date. The CYPs are found in the 
endoplasmic reticulum of the liver cell.   
  
One of the most important of the CYPs for drug metabolism is CYP3A4.  In this 
nomenclature for CYP3A4, 3 is for the family of enzyme, A for the subfamily, and 4 is the 
enzyme isoform (Figure 2.5).  
 
 
 
Figure 2.5 Cytochrome P450 families, sub-families and isoforms: CYP3A4 (Copyright QUT 
University, Sheila Doggrell) 
 
The classification of CYP enzymes into families, subfamilies and isoforms is based on the 
similarities of the genes encoding for them. CYP3A4 is the most abundantly expressed, and is 
involved in the metabolism of about 50% of clinically used drugs.  CYP2D6 and CYP2C8/9 
are also commonly involved in drug metabolism.  Drug interactions often occur at the level of 
these metabolising enzymes, and will be discussed in more detail in the section on drug 
interactions.  The levels of these enzymes are subject to induction and inhibition, and the 
activity of the enzymes may vary with a subject’s genetic makeup (see Chapter 11). 
 
  2.3.2.1 Induction 
When there is induction of an enzyme, there is an increased rate of metabolism of drugs by 
that enzyme, and this leads to a decreased plasma concentration of drug, so that it may 
become ineffective.  Lowering the concentration of a therapeutic drug may lead to it 
becoming ineffective.  For instance, hyperforin (a component of St John’s Wort), an over-
the-counter medicine for depression, induces CYP3A4.  Use of St John’s Wort can lead to the 
failure of oral contraceptives, which are metabolised by CYP3A4.  To avoid adverse effects, 
low doses of oral contraceptives are used to prevent conception.  When the metabolism of 
oral contraceptives is increased by St John’s Wort, the levels of the oral contraceptives may 
fall below those needed for contraception, resulting in pregnancy. 
 
Cigarette smoke and charbroiled meats induce CYP1A, which is involved in the metabolism 
of paracetamol.  Thus, smokers will have lower plasma levels of paracetamol for the same 
dose as non-smokers.  Lowering the levels of paracetamol will lower the pain relief. 
 
An example of autoinduction is alcohol, where chronic alcohol consumption induces the 
enzyme CYP2E1, which is involved in its metabolism.  This partly explains the tolerance to 
alcohol that develops with repeated administration, whereby the same dose of alcohol makes 
an alcohol-naïve person drunk, with little apparent effect on an alcoholic person, who has 
induced CYP2E1, with greater metabolism and inactivation of alcohol.   
 
  2.3.2.2 Inhibition 
Conversely, the plasma levels of drugs may be increased when there is inhibition of 
enzymes.  Thus, inhibition of enzymes will lead to a decreased rate of metabolism, and 
increased plasma concentration of drugs.  Under these circumstances, a therapeutic drug may 
become a toxic drug.  It was recently discovered that components of grapefruit juice are 
potent inhibitors of CYP3A4, and this can lead to dangerously high levels of the many drugs 
that are normally metabolised by this enzyme.  Consequently, it is advisable not to take drugs 
at breakfast with a grapefruit or grapefruit juice, as this may lead to drug toxicity. 
 
Ketoconazole, a commonly used anti-fungal agent is a potent inhibitor of CYP3A4.  Thus, 
ketoconazole will increase the plasma concentrations of the drugs metabolised by this CYP, 
which includes the anti-HIV viral protease inhibitors.  The anti-HIV viral protease 
inhibitors have the potential to be quite toxic, especially if their levels are raised.   
 
 2.3.3 Phase II: Conjugation 
The second phase of drug metabolism is conjugation, which is a Phase I metabolite joining 
to another compound.  Conjugation is very important, as this is the phase that increases the 
water solubility of the drug, which is needed to allow excretion of the drug.  The conjugation 
substates are naturally occurring substances with the most common Phase II conjugation 
products being glucuronides and sulphates.  Glucuronic acid is a product of glucose 
metabolism, and conjugation with glucuronic acid forms glucuronide metabolites.  In 
addition to increasing water solubility, conjugation with glucuronic acid has another 
important function, it inactivates the drug.  This is because the glucuronide metabolites are 
usually inactive. 
 
Some glucuronide metabolites are excreted by the kidney in the urine.  However, many 
glucuronide metabolites are transported in the bile to the gastrointestinal tract and undergo 
enterohepatic recycling (Figure 2.6).  In addition, some glucuronide metabolites are partly 
excreted from the kidney, and partly transported in the bile acid. 
 
Figure 2.6 Entero-hepatic recycling (Copyright QUT, Sheila Doggrell) 
 
In enterohepatic recycling, Drug C arrives at the liver in the circulation.  The metabolism of 
Drug C involves conjugation with glucuronic acid to form Drug C glucuronide, which is 
transported in the bile to the gastrointestinal tract.  Once in the gastrointestinal tract, some of 
the glucuronide is excreted in the faeces, and some of it may be deconjugated by the bacterial 
enzyme β-glucuronidase to yield back the active Drug C, that can be reabsorbed, and taken 
to the liver, with some of the active drug re-entering the circulation. 
 
Many glucuronides undergo this recycling, and this alters their kinetics (the relationship 
between plasma concentration and time).  The plasma levels may be higher than expected 
because the drug is being recycled.  To counter this, the dose of a drug may need lowering.   
An example of a drug that undergoes this recycling is gliclazide, which is used in the 
treatment of type 2 diabetes.  As type 2 diabetes is very common among indigenous 
Australians, it was of interest to determine whether there were any genetic differences in the 
recycling of gliclazide by Caucasians and indigenous Australians.  It was found that there is a 
slight difference, 30% of the dose in Caucasians is recycled compared to 20% in the 
indigenous group.  Theoretically, this means that for the same dose of gliclazide, the plasma 
levels could be lower in the indigenous group meaning the glycaemic control might be 
slightly lower. 
 
When antibiotics are administered they kill the good as well as the bad (disease causing) 
bacteria.  By killing the good bacteria in the gut, antibiotics inhibit bacterial enzyme β-
glucuronidase, which inhibits the enterohepatic recycling.  Without this recycling of a 
glucuronide, plasma drug levels may be lowered, and the drug may become ineffective.  For 
instance, oral contraceptives undergo enterohepatic recycling, and with antibiotic use, the 
plasma levels are reduced, which may lead to the preparations providing less contraceptive 
benefit.  This could result in unplanned/unwanted pregnancy. 
 
2.3.4 First pass metabolism and bioavailability 
The relationship between first pass metabolism and bioavailability has been discussed 
previously (Chapter 1), and is only discussed briefly here.  Drugs with extensive first pass 
liver metabolism have poor bioavailability after oral administration.  An example of a drug 
that undergoes extensive first pass liver metabolism is glyceryl trinitrate (nitroglycerin), 
which is used in the treatment of angina.  Due to this metabolism, glyceryl trinitrate has to be 
administered by other routes of administration.  Glyceryl trinitrate is used sublingually. 
 
When drugs have considerable first pass liver metabolism, but a proportion still gets to the 
systemic circulation, it may be possible to increase the dose of drug, to increase the amount 
of drug that reaches the systemic circulation.  This is the case with the painkillers morphine 
and pethidine.  First pass liver metabolism is also the reason that large doses of the anti-
Parkinson’s drug L-dopa are required to produce effective plasma levels of L-dopa. 
 
In liver disease, the metabolism of certain drugs may be inhibited, increasing bioavailability.  
With increased bioavailability, there will be increased effects of a drug.  Indeed the plasma 
levels maybe increased enough to cause toxic effects.  Thus, in liver disease, it may be 
necessary to decrease the doses of drugs metabolised by the liver.  
 
 2.3.5 Prodrugs 
Prodrugs are pharmacologically inactive drugs that have active metabolites.  They are 
designed so that the maximum amount of active drug reaches the relevant site of action to 
have the required pharmacodynamic effect.  An example of a prodrug is enalaprilat.  
Enalaprilat is a potent inhibitor of angiotensin converting enzyme (ACE), and ACE inhibitors 
are commonly used in cardiovascular disease.  However, it would be pointless to administer 
enalaprilat orally, as it is not absorbed after oral administration.  To circumvent this, the 
pharmacological inactive prodrug enalapril is used.  Enalapril is absorbed and has an oral 
bioavailability of ~60%.  Enalapril is converted by esterases in the liver to enalaprilat, which 
is the beneficial ACE inhibitor.  
 
 2.3.6 Pharmacologically active metabolites 
Some drugs produce pharmacologically active metabolites.  Morphine is a 
pharmacologically active metabolite of heroin.  Morphine acts as an agonist at a particular 
binding site, the opioid μ-receptors, to cause pain relief.  Stimulation of the opioid μ-
receptors also underlies the euphoric effects of morphine, and gives its potential for abuse.  
When morphine is given orally, it undergoes extensive first pass liver metabolism, which 
lowers the concentration.  Morphine only enters the brain slowly.  Thus, only low 
concentrations reach the brain to have an effect. 
 
Heroin is diacetylmorphine, and is more lipid soluble than morphine.  Thus, heroin enters the 
brain more readily than morphine.  Once, in the brain, heroin is metabolised to morphine, 
which gives the pain relief and euphoria.  For the same dose, much higher levels of morphine 
in the brain can be obtained with heroin than morphine.  This is a key factor for opioid 
addicts, who prefer heroin to morphine as their drug of abuse. 
 
 2.3.7 Pharmacological toxic metabolites 
In addition to the metabolites of drug being therapeutic, metabolites may be toxic.  
Paracetamol is considered by many to be a relatively safe drug.  It is considered safe enough 
to be sold without a prescription.  Normally most of the paracetamol is conjugated and 
excreted in urine (Figure 2.7). 
 
Figure 2.7 Metabolism of paracetamol (Copyright QUT, Sheila Doggrell) 
 
However, a small amount of paracetamol is metabolised by the CYP enzyme system to 
NAPQI.  NAPQI is potentially very toxic to the liver.  Fortunately small amounts of NAPQI, 
in the presence of glutathione, are readily excreted in the urine.  Thus, normally, we do not 
observe toxicity with paracetamol.  However, when high doses of paracetamol are 
administered, the glutathione gets used up, NAPQI levels build up, and become toxic.  The 
main feature of paracetamol poisoning is liver failure.  Paracetamol poisoning will be 
discussed further under treatment of poisoning. 
 
2.4. Drug Elimination 
 2.4.1 Introduction 
The most common way from administration of drug to elimination is by liver metabolism and 
kidney excretion (Figure 2.8).  After oral administration, drugs are taken from the 
gastrointestinal tract in the circulation for metabolism in the liver. 
 
Figure 2.8 Drug Elimination (Copyright QUT, Sheila Doggrell) 
 
Drugs administered by other routes (e.g. sublingual, via injection) also end up in the 
circulation being carried to the liver for metabolism.  After metabolism in the liver, the 
metabolites are carried in the circulation to the kidney for excretion in the urine.  A few drugs 
are excreted without metabolism.  Some drug metabolites are transported in the bile to the 
gastrointestinal tract, where they may be recycled or eliminated in the faeces. 
 
2.4.2 Kidney 
  2.4.2.1 Introduction 
The kidney is the most important site for excreting drugs.  Drugs are eliminated from the 
body either after conversion to metabolites that are excreted, or they are excreted unchanged. 
 
Kidney function and drug excretion varies with the life cycle.  When renal function is low or 
impaired, the excretion of drugs may be reduced, leading to a build-up of drug and toxicity.  
For instance, renal function is low in the neonate but matures rapidly in the first few months 
of life.  This means that neonates may need very small doses, even measured as per kilogram, 
compared to older people.  After maturation, kidney function declines about 1% per year in 
adulthood.  Thus, older-adults (≥ 65 years) may have functional kidney impairment, and 
require small doses of drugs that undergo excretion from the kidney than the doses used in 
younger adults.  
 
The first step in excretion from the kidney is glomerular filtration.  Drugs are delivered to the 
kidney in the blood stream, and free drug (water soluble or free fraction of lipid soluble 
drugs), with the exception of macromolecular substances (heparin), freely diffuse into 
glomerular filtrate.  Drugs bound to albumin (e.g. warfarin) are held back.  Free warfarin 
and most other drugs/drug metabolites are freely filterable.  Some drugs are actively secreted 
into the kidney tubules. 
 
2.4.2.2 Secretion and Reabsorption 
In the adult there are about a million kidney tubules.  In these tubules, movement out of the 
tubule into the interstitial fluid, and, hence, to the blood is known as reabsorption.  Movement 
of substances into the tubules is known as secretion (Figure 2.9). 
 
Figure 2.9 Reabsorption and secretion from kidney tubule (Copyright QUT, Sheila Doggrell) 
 
Lipid soluble drugs are readily reabsorbed, so they will continue to be recycled back into 
circulation.  It is only when drugs are water soluble that they remain in the kidney tubule to 
be excreted. 
 
Endogenous compounds that are positively charged (choline, dopamine) are actively secreted 
into the proximal tubule using transporters.   Many positively charged drugs can be secreted 
on these transporters (e.g. ranitidine), and are excreted following active transport into the 
urine.  Similarly, endogenous compounds that are negatively charged are also secreted into 
the proximal tubule via transporters, and drugs can use this transporter.  Drugs secreted using 
this transporter include the ACE inhibitor captopril. 
 
The drug probenecid has two distinct actions on the kidney.  The first action is related to uric 
acid.  Uric acid (one of the body’s waste products) is actively reabsorbed from the kidney 
tubule, and an excessive accumulation of urate in the plasma leads to gout.  The pain of gout 
is due to crystals of urate in the joints.  Some drugs used to treat gout are known as uricosuric 
agents.  The uricosuric agents (e.g. probenecid) inhibit the reabsorption to promote the 
excretion of urate, and prevent the accumulation of urate in joints.  The second action of 
probenecid relates to penicillin levels.  Penicillin is rapidly eliminated from the body, as 90% 
of penicillin is secreted into the proximal tubule, and excreted.  Thus, after administration, the 
levels and effectiveness of penicillin declines rapidly.  However, this can be inhibited by 
probenecid.   Thus, probenecid can be used to increase and prolong the plasma levels of 
penicillin, to increase the effectiveness of penicillin. 
 
  2.4.2.3 Renal insufficiency 
In renal insufficiency, (e.g in neonates, and with age-related renal impairment), the duration 
of action of drugs excreted unchanged from the kidney is prolonged.  Examples of drugs 
excreted unchanged by the kidney include the aminoglycoside antibiotics.  The levels of 
these drugs may increase in renal insufficiency and produce toxicity.  Both of these drugs 
have a small therapeutic window, which means that the concentrations that cause toxicity 
effects are only slightly above the concentrations that cause a therapeutic effect. The toxicity 
with aminoglycosides includes ototoxicity (ringing in ears to deafness).  Digoxin is used to 
increase the force of the heart beat in heart failure, and has a small therapeutic window, with 
toxicity including cardiac arrhythmias.  When renal excretion is impaired, it may be 
necessary to decrease the dose of these drugs and/or increase the dose interval. 
 
Clearance is term given to the combination of metabolism and excretion of a drug.  When a 
drug is metabolised by the liver and the metabolite is excreted via thekidney, renal 
insufficiency can lead to increased plasma concentrations and adverse effects.  Thus, we need 
to lower doses when there is kidney insufficiency.  But how do we know when there is renal 
insufficiency? We assess kidney function.  
 
Kidney function is assessed from the creatinine clearance.  Creatinine clearance is the 
removal of creatinine from the body.  Creatinine is natural metabolite of creatine (found in 
muscle).  The properties that make creatinine ideal for assessing kidney function are that 
creatinine has a steady level in the blood and is freely filtered by the kidney.  Thus, with 
normal function, the plasma and urine levels of creatinine will be similar.  In kidney 
insufficiency plasma creatinine levels are increased, and urine levels are decreased. 
 
When creatinine clearance is inhibited, this indicates renal insufficiency, and that it may be 
necessary to decrease the dose of drug to avoid toxicity.  This can occur with morphine in 
renal insufficiency.  An important metabolite of morphine is morphine-6-glucuronide, 
which has similar pharmacological actions to morphine.  Morphine-6-glucuronide is excreted 
from kidney.  In renal insufficiency, morphine-6-glucuronide builds up and increases efficacy 
(pain relief).  Unfortunately, increased levels of morphine-6-glucuronide also lead to an 
increased likelihood of adverse effects, such as respiratory depression.  In elderly patients, 
lower doses of morphine are used partly to compensate for loss of kidney function  
 
 2.4.3 Other routes of excretion 
Anaesthetic gases are administered by inhalation, and are also excreted from the lung. 
 
Some drugs are excreted in breast milk, and the excreted drugs are a source of unwanted 
effects in the nursing infant.  For instance, morphine and other lipid soluble drugs are 
excreted in breast milk.  While it is best to avoid all drugs during breast feeding, there are 
some breast feeding women who need to take medications.  Epileptic mothers may have to 
continue their medication.  Some of the older anti-epileptic drugs e.g. diazepam, are known 
to get into breast milk and should be avoided during breast feeding.  There is little 
information about whether the newer agents get into breast milk, but it is considered that the 
levels are likely to be too low to have effects in the new-born. 
 
2.5. Blood levels 
 2.5.1 Introduction 
When using drugs as therapeutics, the aim is to produce a specific effect. In most cases, to 
achieve this it is necessary to get the drug into the plasma at concentrations high enough to 
produce the effect.  However, it is also important not to administer too much drug, as this 
could lead to a range of non-specific toxic effects.  As can be seen in Figure 2.10, the ideal 
plasma concentration range is between the minimum concentration required to be effective 
(minimum effective concentration or MEC) and the concentration, above which toxic effects 
are seen (minimum toxic concentration).   
 
 
 
Figure 2.10 Minimum effective and toxic concentrations (Copyright Monash University, Liz 
Davies) 
 
Graphs are used to describe the relationship between blood levels of drugs over time.  From 
these graphs, we can learn things about drugs that help us to determine how to use them in 
people. 
 
2.5.2 Elimination half-life 
The elimination half-life is the time from the maximum concentration to half maximum 
concentration.  The elimination half-life is dependent on the rates of metabolism and 
elimination of the drug.  Thus, slowly metabolised and slowly eliminated drugs will have 
long half-lives.  Whereas, rapidly metabolised and rapidly eliminated drugs will have short 
half-lives.  The half-life is an important determinant of the frequency a drug needs to be 
administered.  Drugs with short half-lives need to be given more often than those with long 
half-lives. 
 
Provided there is a method for measuring the levels of the drug in the plasma, we can 
graphically plot the drug concentration against time (Figure 2.11). 
  
Figure 2.11 Elimination half-life (Copyright QUT, Sheila Doggrell) 
 
In Figure 2.11, Drug A was administered intravenously, giving a maximum concentration 
straight away, and then the concentration diminishes over time, as the drug is metabolised 
and excreted.  The elimination half-life is the time from the maximum concentration to half 
maximum concentration.  Thus, we need to determine the 50% maximal response, and then 
determine the time from maximal to half-maximal response, which with Drug A is about 4.4 
hours.  Drug A will have to be administered at least 2 times a day, and maybe more, as it is 
rapidly metabolised and/or eliminated.   
 
Elimination half-lives can also be determined when drugs are administered orally.  When 
Drug B is administered orally, it has to be absorbed into the blood stream, so blood levels rise 
slowly over time to a maximum.  Once again, the elimination half-life is the time from the 
maximum concentration to half maximum concentration.  So we need to estimate the time of 
the maximal response, which is about 6.2 hours for Drug B.  The levels of Drug B have fallen 
to half-maximal after 13.4 hours.  Thus, the elimination half-life is 13.4 – 6.2 hours, which is 
7.2 hours.  Drug B may be suitable for administration 2 times a day or less, as it is less 
quickly metabolised and/or eliminated than Drug A. 
 
The elimination half-live is a constant and a unique feature of each drug.  Thus, if drug A had 
been administered orally, the elimination half-life would still be 4.4 hours.  If drug B had 
been administered intravenously, the elimination half-life would be 7.2 hours 
 
 2.5.3 First and zero order kinetics 
Graphs of plasma levels against time, can also tell us about the kinetics of the metabolism of 
the drug (Figure 2.12). 
 
Figure 2.12 Metabolism and Kinetics (Copyright QUT, Sheila Doggrell) 
 
With most drugs, there is a rapid fall in drug levels, as most drugs are readily metabolised, 
and there is an excess of enzyme available for the metabolism.  Thus, the enzyme never 
becomes saturated with drug.  This is known as first order kinetics (top, Figure 2.12).  In 
first order kinetics, increasing the concentration of the drug increases the metabolism of the 
drug.  First order kinetics is also observed with drugs that are eliminated unchanged. 
 
With some drugs there is a limited amount of enzyme available to metabolise the drug, and 
when that limit is reached, metabolism occurs at a constant rate.  Thus, the enzyme becomes 
saturated with drug.  This is known as zero order kinetics, and is seen as a straight line on 
the graph (bottom, Figure 2.12).  In zero order kinetics, increasing the concentration of drug 
above a certain point does not increase the rate of metabolism.  The best known example of 
zero order kinetics is alcohol.  There are no notable examples of therapeutic drugs that have 
saturable metabolism and zero order kinetics.  However, some therapeutic drugs taken in 
excess can have saturable kinetics.  Examples include aspirin and the anti-epileptic drug 
phenytoin. 
 
 2.5.4 Minimum effective and steady-state concentrations  
The Minimum Effective Concentration (MEC) is the minimum plasma concentration 
required for the drug to be effective.  When we use drugs, we want to use the appropriate 
dose and dosing interval to achieve plasma concentrations about the MEC to give an ongoing 
beneficial effect. 
 
The steady-state concentration is a reasonably even concentration achieved with repeat 
dosing or continued infusion, which gives a continued beneficial effect. 
 
 2.5.5 Maintenance doses and loading doses 
 
A maintenance dose is a small, fixed dose.  When you use maintenance doses, it may take 
long time to reach the minimum effective concentration, as the plasma concentration only 
slowly builds up to reach and then exceed the minimum effective concentration (top, Figure 
2.13).  This is an inappropriate way to administer drugs in serious conditions or emergency 
situations, where you need the drug to be effective immediately. 
 
With some drugs, especially those with a large volume of distribution, it may be necessary to 
give a loading dose (a big dose) initially to get above the minimum effective concentration 
and get the beneficial effect quickly.  In such situations, a loading dose is used to reach the 
minimum effective concentration, and then maintenance doses are given to maintain the 
minimum effective concentration (bottom, Figure 2.13).  With a loading dose, the minimum 
effective concentration is reached much quicker than using the maintenance dose. 
 
Figure 2.13 Maintenance doses and loading dose (Copyright QUT, Sheila Doggrell) 
 
An example of a drug that is used with a loading dose and maintenance doses is the anti-
platelet drug clopidogrel.  Intravenous clopidogrel is given as a loading dose in percutaneous 
coronary intervention to prevent clotting straightaway, and this is followed by oral 
maintenance doses to prevent coagulation, as the subject recovers from the surgery. 
 
Steady-state concentrations are eventually reached with both maintenance and 
loading/maintenance dosing (Figure 2.13). 
 
